Ginkgolide (GDL) treatment inhibits astrocyte activation and the expression of IL-1β and TNF-α, enhances cell viability, and reduces peri-scar astrocyte reactivity, creating favorable conditions for post-stroke recovery (Li X. et al., 2020). Here, IL1B is linked to stroke disorder.